In a highly unusual move, the pharmaceutical industry trade group in the United Kingdom has extended a suspension given Astellas last year for another 12-month period, after finding the drug maker engaged in yet another round of egregious behavior.
The latest infractions demonstrated “wholly inadequate oversight and control” at its U.K. and European operations and a “lamentable lack of concern for patient safety,” according a stern statement issued by the Association of the British Pharmaceutical Industry.
About the Author Reprints
